Mesoblast secures A$170m private placement
This article was originally published in Scrip
Executive Summary
Both US and Australian investors were suitably impressed by regenerative medicine firm, Mesoblast, allowing it to raise A$170 million ($176 million), through the completion of a private placement of its shares. The company now has cash reserves of around A$332 million.